KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $71.6 million.

  • Emergent BioSolutions' Change in Receivables rose 18699.88% to $71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 21551.34%. This contributed to the annual value of $24.4 million for FY2024, which is 1296.3% up from last year.
  • Per Emergent BioSolutions' latest filing, its Change in Receivables stood at $71.6 million for Q3 2025, which was up 18699.88% from -$118.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Change in Receivables ranged from a high of $132.4 million in Q2 2023 and a low of -$118.5 million during Q2 2025
  • For the 5-year period, Emergent BioSolutions' Change in Receivables averaged around -$1.6 million, with its median value being -$4.0 million (2022).
  • Within the past 5 years, the most significant YoY rise in Emergent BioSolutions' Change in Receivables was 341000.0% (2023), while the steepest drop was 56907.89% (2023).
  • Emergent BioSolutions' Change in Receivables (Quarter) stood at -$98.5 million in 2021, then soared by 63.86% to -$35.6 million in 2022, then dropped by 3.65% to -$36.9 million in 2023, then soared by 308.94% to $77.1 million in 2024, then decreased by 7.13% to $71.6 million in 2025.
  • Its Change in Receivables was $71.6 million in Q3 2025, compared to -$118.5 million in Q2 2025 and $73.3 million in Q1 2025.